Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

  • Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact
    • Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications
    • Entresto (USD 84 million) steadily growing with better access in US and EU
    • Gilenya (USD 722 million, +5% cc) grew mainly driven by volume
    • Excluding Gleevec/Glivec, Oncology grew +7% (cc) driven mainly by Promacta/Revolade, Jakavi, Tafinlar + Mekinist and Tasigna
  • Core[1] operating income down 5% (cc) due to generic erosion and increased investments, mainly …
/by